Please assess the completion status of the following clinical trial:

Trial Title: Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic Brain Injury (TBI) or Subarachnoid hemorrhage (SAH)~* Admitted to the hospital less than 48 hours prior to randomization~* Glasgow Coma Scale (GCS) score 3-8 (inclusive), or GCS motor score of five or less and abnormal CT scan showing intracranial pathology~* Hemodynamically stable~* Older than 18 years of age~Exclusion Criteria:~* No IV access~* Spinal cord injury~* History of or CT confirmation of previous brain injury, including brain tumor, stroke, or a spontaneous intracerebral hemorrhage~* Hemodynamically unstable~* Suspected anoxia~* Liver failure~* Younger than 18 years of age~* Pregnant~* Allergy to phenytoin or lacosamide~* Inability to obtain consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lacosamide (Type: EXPERIMENTAL): The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
- phenytoin (Type: ACTIVE_COMPARATOR): the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.

Based on this trial design, predict the completion outcome and termination type (if applicable).